Abstract: A water-mediated process prepares a polymeric (meth)acrylation composition. In some embodiments, the process includes providing a stabilized aqueous solution including a (meth)acrylation component and a polyol monomer in a vessel under an inert atmosphere and adding a diacid monomer to the vessel under the inert atmosphere. In some embodiments, the process includes providing a stabilized aqueous solution including a (meth)acrylation component and a copolymer of a polyol monomer and a diacid monomer in a vessel under an inert atmosphere. The process further includes heating and removing water from the vessel under the inert atmosphere to produce the polymeric (meth)acrylation composition. The polymeric (meth)acrylation composition includes a (meth)acrylation polyester copolymer of the diacid monomer and the polyol monomer with the (meth)acrylation component conjugated to the (meth)acrylation polyester copolymer.

Abstract: In some embodiments, a polymer film includes a base composition of poly(ethylene-vinyl acetate) and a surface composition comprising hydroxy groups. In some embodiments, a polymer film includes a base layer of a first composition of poly(ethylene-vinyl acetate), a surface layer at a surface of the base layer, and a coating layer of a second composition of a copolymer of glycerol and sebacic acid. The surface layer includes surface hydroxy groups converted from acetate groups of the poly(ethylene-vinyl acetate). The second composition is attached to the surface layer by ester bonds between carboxyl groups of the copolymer and the hydroxy groups. A single-use bioreactor bag includes a polymer film including a base composition of poly(ethylene-vinyl acetate) and a surface composition comprising hydroxy groups. A method of modifying a poly(ethylene-vinyl acetate) film includes converting acetate groups at a first surface of the poly(ethylene-vinyl acetate) film to hydroxy groups.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A water-mediated process prepares a polymeric (meth)acrylation composition. In some embodiments, the process includes providing a stabilized aqueous solution including a (meth)acrylation component and a polyol monomer in a vessel under an inert atmosphere and adding a diacid monomer to the vessel under the inert atmosphere. In some embodiments, the process includes providing a stabilized aqueous solution including a (meth)acrylation component and a copolymer of a polyol monomer and a diacid monomer in a vessel under an inert atmosphere. The process further includes heating and removing water from the vessel under the inert atmosphere to produce the polymeric (meth)acrylation composition. The polymeric (meth)acrylation composition includes a (meth)acrylation polyester copolymer of the diacid monomer and the polyol monomer with the (meth)acrylation component conjugated to the (meth)acrylation polyester copolymer.

Abstract: A suture-free stent graft is disclosed including a woven graft tube having woven extensions extending from an outer face of the woven graft tube. Each of the woven extensions is integrally woven with the woven graft tube such that warp from the woven graft tube is de-interlaced from at a first end and re-interlaced at a second end. Supplemental warp is interlaced into the woven graft tube in replacement of the deinterlaced warp so as to maintain weave density in the woven graft tube under the woven extensions. The woven extensions and portions of the woven graft tube disposed directly under the woven extension have independent weft from one another. A suture-free stent graft construct is disclosed including the suture-free stent graft and at least one stent wire disposed about the suture-free stent graft, at least partially disposed between the woven graft tube and the woven extensions at securement sites.

Abstract: A first process includes suturelessly fixing a surface-modified polyester textile to Nitinol wire. The surface-modified polyester textile includes a textile of a polyester having a modified surface that provides surface crosslinkable groups. A first composition includes a Nitinol layer, a passivation layer bound to the Nitinol layer, a surface-modified polyester layer, and a tie layer binding the surface-modified polyester layer to the passivation layer. A first implantable device includes a Nitinol wire, a passivation layer bound to the Nitinol wire, a surface-modified polyester textile, and a tie layer binding the surface-modified polyester textile to the passivation layer such that the surface-modified polyester textile is suturelessly fixed to the Nitinol wire. A second implantable device and a second composition include a polymer of glycerol and sebacic acid including a catechol group. A second process includes forming a polymer of glycerol and sebacic acid including a catechol group.

Abstract: A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.

Abstract: A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.

Abstract: A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores.

Abstract: A manufacturing process forms a bored hollow lumen. The manufacturing process includes providing a solid rod of a bioresorbable material and boring a hole axially through the solid rod. The manufacturing process also includes modifying surface defects formed on a luminal surface by the boring, the luminal surface defining the hole, thereby forming the bored hollow lumen. A bored hollow lumen includes a lumen wall including a bioresorbable material. The lumen wall has an abluminal surface and a luminal surface. The luminal surface defines a bore through the bored hollow lumen. The bioresorbable material has a uniform crosslinking density.

Abstract: A cryopreservation process includes combining a cryopreservation composition with a biological sample. The cryopreservation composition includes at least one glycerol ester component. The cryopreservation process also includes then cooling the cryopreservation composition with the biological sample to a cryopreservation temperature. The cryopreservation composition aids in cryopreserving the biological sample at the cryopreservation temperature. A cryopreservation composition includes at least one glycerol ester component. A cryopreserved system includes a biological sample in a cryopreservation composition at a cryopreservation temperature. The cryopreservation composition includes at least one glycerol ester component.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A leaflet for a heart valve replacement includes poly(glycerol sebacate) urethane. A heart valve replacement includes a leaflet including poly(glycerol sebacate) urethane. A process forms a leaflet for a heart valve replacement. The process includes casting a first solution including poly(glycerol sebacate) and isocyanate to form a leaflet composition including poly(glycerol sebacate) urethane. The process also includes shaping the leaflet composition to form the leaflet.

Abstract: A biocontainment vessel includes a vessel structure including a structural composition and an enhancement composition associated with the structural composition. The enhancement composition includes a co-polymer. The co-polymer is a poly(glycerol sebacate) or a poly(glycerol sebacate urethane). The enhancement composition may also include an augmentation agent associated with the co-polymer. The enhancement composition is located with respect to the structural composition such that the enhancement composition benefits biological cells contained in the biocontainment vessel. A composition includes a co-polymer and an augmentation agent contained by the co-polymer. A method of containing biological cells includes placing the biological cells in an augmented biocontainment vessel and storing them in the augmented biocontainment vessel under predetermined conditions. An augmented substrate includes a substrate and an enhancement composition coating a surface of the substrate.

Abstract: A delivery system is described that includes a controlled release device that includes a crosslinked poly(glycerol sebacate) (PGS) or other glycerol ester and a controlled release compound, the controlled release device being provided in a contracted state and being expandable to a three-dimensional expanded state in a target location. The delivery systems provides an expandible, flexible biodegradable elastomer loaded with an active ingredient to allow for extended release for different dosage forms for either human or animal health products in vivo, delivered through the gastrointestinal tract.

Abstract: A composite lumen includes a braided structure infused with an impermeable elastic sealer. The braided structure has an inner diameter of 3 mm or less and a braid angle greater than 100°. The braided structure also has a wall thickness to inner diameter ratio greater than 0.02, picks per inch from between about 25 and about 135, and a number of ends between about 12 and about 48, with a braid pattern that is selected from 1×1, 2×2, or 2×1 and with an effective yarn denier (yarn denier×ply number) greater than 45.

Abstract: A cell selection and sorting process includes attaching cells of a target cell type to a first set of polymeric beads, washing the chamber through a first filter having a first pore size less than the first bead diameter to retain the first set of polymeric beads and greater than a cell diameter to remove unattached cells, releasing the cells of the target cell type from the first set of polymeric beads, and collecting the cells of the target cell type. A cell modification process includes modifying cells of the target cell type in the chamber. A cell modification system includes a cell modification chamber with entry ports and outlet ports, filters with predetermined pore sized selectably located on the outlet ports, and sets of polymeric beads with predetermined diameters being selected such that the sets of polymeric beads are separable by the filters.

Abstract: A biocontainment vessel includes a vessel structure including a structural composition and an enhancement composition associated with the structural composition. The enhancement composition includes a co-polymer. The co-polymer is a poly(glycerol sebacate) or a poly(glycerol sebacate urethane). The enhancement composition may also include an augmentation agent associated with the co-polymer. The enhancement composition is located with respect to the structural composition such that the enhancement composition benefits biological cells contained in the biocontainment vessel. A composition includes a co-polymer and an augmentation agent contained by the co-polymer. A method of containing biological cells includes placing the biological cells in an augmented biocontainment vessel and storing them in the augmented biocontainment vessel under predetermined conditions. An augmented substrate includes a substrate and an enhancement composition coating a surface of the substrate.

Abstract: A pH-modulating poly(glycerol sebacate) composition includes poly(glycerol sebacate) and at least one pH-modulating agent associated with the poly(glycerol sebacate). A process of making a pH-modulating poly(glycerol sebacate) composition includes forming a poly(glycerol sebacate) by a water-mediated reaction from glycerol and sebacic acid and associating at least one pH-modulating agent with the poly(glycerol sebacate). A process of modulating a pH of a buffered aqueous solution includes placing a pH-modulating poly(glycerol sebacate) composition in a buffered aqueous solution. The pH-modulating agent is released into the buffered aqueous solution during degradation of the poly(glycerol sebacate) to reduce a decrease in pH of the buffered aqueous solution caused by degradation of the poly(glycerol sebacate).